<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Barreto, Andrew D.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Argatroban Safe and Promising as Monotherapy or Combined with Tissue Plasminogen Activator</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">27-28</style></pages><abstract><style  face="normal" font="default" size="100%">This article presents data from three clinical trials, and also discussed off-label use of argatroban for ischemic stroke. The results demonstrated positive clinical outcomes, indicating that argatroban appears to be safe and promising, both as monotherapy and in combination with intravenous tissue plasminogen activator (t-PA) for patients with ischemic stroke.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>